Biotheus Reports Collaboration Expansion with Hansoh Pharma to Develop EGFR/cMET Bispecific Antibody-Drug Conjugates
Shots:
- Biotheus and Hansoh Pharma have expanded their partnership for the development of EGFR/cMET bispecific ADCs by leveraging Hansoh's ADC platform technology and Biotheus' bispecific Ab
- Under the collaboration, Hansoh Pharma gains exclusive global rights to develop, produce and commercialize PM1080/HS-20117 with the right of sublicense while Biotheus is entitled to receive ~$0.69B up front as well as payment on achieving milestones along with global net-sales-based tiered royalties
- PM1080/HS-20117, under ongoing P-I clinical evaluation, is a bispecific Ab that targets EGFR and cMet to inhibit the growth and survival of tumors
Ref: Biotheus | Image: Biotheus
Related News:- Biotheus and Bitterroot Bio Join Forces for the Development of Bispecific Proteins in Cardio-Immunology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
